We are giving life to new classes of medicine to change the lives of patients with devastating diseases

We are giving life to new classes of medicine to change the lives of patients with devastating diseases

Strong track record of clinical success, outperforming the biopharma industry average by 6x1
0
New therapeutics and therapeutic candidates generated from PureTech's R&D engine
0
Clinical indications being pursued by PureTech or its Founded Entities
0
Has been filed for FDA approval
0
Taken from inception at PureTech to FDA and EU regulatory clearances
Unlocking the Potential of Validated Efficacy
We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine
Seasoned Senior Leadership
Our team has overseen R&D of therapeutics supporting more than 20 regulatory approvals and led several multi-billion dollar strategic transactions
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

News & Press

Press releases
2024-06-18
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
Press releases
2024-06-13
Results of Annual General Meeting

Calculated based on the aggregate PureTech data including all therapeutic candidates advanced through at least Phase 1 by PureTech or its Founded Entities from 2009 onward and the industry average data. Industry average data measures the probability of clinical trial success of therapeutics by calculating the number of programs progressing to the next phase vs. the number progressing and suspended (Phase 1=52%, Phase 2=29%, Phase 3=52%). BIO, PharmaIntelligence, QLS (2021) Clinical Development Success Rates 2011-2020. This study did not include therapeutics regulated as devices.